Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).
종목 코드 NNNN
회사 이름Anbio Biotechnology
상장일Feb 19, 2025
CEOLau (Michael)
직원 수27
유형Ordinary Share
회계 연도 종료Feb 19
주소Friedrich-Ebert-Anlage 49
도시FRANKFURT AM MAIN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Germany
우편 번호60308
전화4916096247281
웹사이트https://anbiobiotechnology.com/
종목 코드 NNNN
상장일Feb 19, 2025
CEOLau (Michael)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음